ClinicalTrials.gg
CompletedNCT00596466Updated Jan 26, 2021Results posted

Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

A Phase 3 interventional study of pregabalin in Epilepsy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 44 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies testing pregabalin in Epilepsy — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsy.

Enrollment
9th of 12
75 · median 194
Started
2008
with 1 other
Phase 3
9 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
12 of 12
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 12 studies testing pregabalin in Epilepsy, this one is the 9th largest by enrollment, is one of 2 that started in 2008, is one of 9 in phase 3, and was the 10th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 12 studies testing pregabalin in Epilepsy is open now. The open studies under Epilepsy, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 112 (39%) set no upper age limit and 149 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing pregabalin in Epilepsy as a file.
02

Study summary

This study will evaluate the long term safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy patients for the treatment of partial seizures. This is an extension study to a previous clinical trial.

03

Conditions studied

  • Epilepsy

Keywords

  • open-label
  • extension study
  • pregabalin
  • partial epilepsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed the previous protocol and wish to continue to receive pregabalin.
  • Diagnosis of epilepsy with partial seizures

Exclusion criteria

Exclusion Criteria:

  • Early withdrawal from the previous protocol, an episode of status epliepticus, or primary generalized epilepsy.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    1

    Drug: pregabalin

Interventions

06

What researchers measure

Primary outcomes

  1. Seizure Frequency

    Time frame: Baseline up to Week 28

  2. Number of Participants With (All Causality) Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: Baseline up to Week 28

  3. Number of Participants With Laboratory Test Values of Potential Clinical Importance

    Pre-defined criteria were established for each laboratory test (hematology, blood chemistry and urinalysis) to define the values that would be identified as of potential clinical importance.

    Time frame: Baseline up to Week 28

07

Results

Posted Sep 11, 2012

Participant flow

Participant flow — Overall Study
MilestonePregabalin
Started75
Enrolled, treated73
Completed58
Not completed17
Withdrew: Lack of efficacy5
Withdrew: Adverse event4
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation2
Withdrew: Unpecified2
Withdrew: Enrolled, not treated2

Outcome measures

PrimarySeizure Frequency
Time frame:
Baseline up to Week 28

No measurements were reported for this outcome.

PrimaryNumber of Participants With (All Causality) Adverse Events (AEs) and Serious Adverse Events (SAEs)

Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Participants with multiple occurrences of an AE within a category were counted once within the category.

Time frame:
Baseline up to Week 28
Reported as:
Number · Participants
Number of Participants With (All Causality) Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPregabalin
Non-serious AEs30
Serious AEs (SAEs)3
PrimaryNumber of Participants With Laboratory Test Values of Potential Clinical Importance

Pre-defined criteria were established for each laboratory test (hematology, blood chemistry and urinalysis) to define the values that would be identified as of potential clinical importance.

Time frame:
Baseline up to Week 28
Reported as:
Number · Participants
Number of Participants With Laboratory Test Values of Potential Clinical Importance
ParticipantsPregabalin
Number of Participants With Laboratory Test Values of Potential Clinical Importance17

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—3/73 (4.1%)14/73 (19.2%)
Most frequent serious events
Most frequent serious events
EventPregabalin
ConvulsionNervous system disorders2/73
Road traffic accidentInjury, poisoning and procedural complications1/73
Transient ischaemic attackNervous system disorders1/73
Most frequent other events
Most frequent other events
EventPregabalin
NauseaGastrointestinal disorders4/73
HeadacheNervous system disorders4/73
Weight increasedInvestigations3/73
ArthralgiaMusculoskeletal and connective tissue disorders3/73
ConvulsionNervous system disorders3/73

Baseline characteristics

Age, Customized
Age, Customized(Participants)Pregabalin
18-44 years48
45-64 years23
Greater than or equal to (≥) 65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin
Female38
Male37
08

Study locations

44 sites
  • Pfizer Investigational Site
    Phoenix, Arizona 85003, United States
  • Pfizer Investigational Site
    Fayetteville, Arkansas 72703, United States
  • Pfizer Investigational Site
    Fullerton, California 92835, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Modesto, California 95355, United States
  • Pfizer Investigational Site
    Murrieta, California 92562, United States
  • Pfizer Investigational Site
    Newport Beach, California 92660, United States
  • Pfizer Investigational Site
    Temecula, California 92591, United States
  • Pfizer Investigational Site
    Denver, Colorado 80204, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32209, United States
  • Pfizer Investigational Site
    Suwanee, Georgia 30024, United States
  • Pfizer Investigational Site
    Danville, Indiana 46122, United States
  • Pfizer Investigational Site
    Fort Wayne, Indiana 46805, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66160, United States
  • Pfizer Investigational Site
    Bowling Green, Kentucky 42101, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40536, United States
  • Pfizer Investigational Site
    Houma, Louisiana 70363, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71105-5634, United States
  • Pfizer Investigational Site
    Pikesville, Maryland 21208, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01608, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48202, United States
  • Pfizer Investigational Site
    Flowood, Mississippi 39232, United States
  • Pfizer Investigational Site
    Great Falls, Montana 59405, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28203, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28209, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    Houston, Texas 77074, United States
  • Pfizer Investigational Site
    Temple, Texas 76508, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84107, United States
  • Pfizer Investigational Site
    West Jordan, Utah 84088, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • Pfizer Investigational Site
    Beroun, 266 01, Czechia
  • Pfizer Investigational Site
    Brno 2, 602 00, Czechia
  • Pfizer Investigational Site
    Litomysl, 570 14, Czechia
  • Pfizer Investigational Site
    New Territories, Hong Kong
  • Pfizer Investigational Site
    Dnipropetrovsk, 49005, Ukraine
  • Pfizer Investigational Site
    Dnipropetrovsk, 49115, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 61018, Ukraine
  • Pfizer Investigational Site
    Kharkiv, 61068, Ukraine
  • Pfizer Investigational Site
    Lugansk, 91045, Ukraine
  • Pfizer Investigational Site
    Odessa, 65025, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2008
First posted
Jan 17, 2008
Start
Apr 2008
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Sep 11, 2012
Last update
Jan 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00596466
Responsible party
Sponsor
First posted
Jan 17, 2008
Start date
Apr 2008
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Sep 11, 2012
Last update
Jan 26, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion